These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
362 related articles for article (PubMed ID: 28053024)
1. Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer. Walz A; Ugolkov A; Chandra S; Kozikowski A; Carneiro BA; O'Halloran TV; Giles FJ; Billadeau DD; Mazar AP Clin Cancer Res; 2017 Apr; 23(8):1891-1897. PubMed ID: 28053024 [TBL] [Abstract][Full Text] [Related]
2. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor. Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749 [TBL] [Abstract][Full Text] [Related]
3. Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses. Sahin I; Eturi A; De Souza A; Pamarthy S; Tavora F; Giles FJ; Carneiro BA Cancer Biol Ther; 2019; 20(8):1047-1056. PubMed ID: 30975030 [TBL] [Abstract][Full Text] [Related]
4. Glycogen synthase kinase-3beta: a prognostic marker and a potential therapeutic target in human bladder cancer. Naito S; Bilim V; Yuuki K; Ugolkov A; Motoyama T; Nagaoka A; Kato T; Tomita Y Clin Cancer Res; 2010 Nov; 16(21):5124-32. PubMed ID: 20889919 [TBL] [Abstract][Full Text] [Related]
5. GSK-3β in DNA repair, apoptosis, and resistance of chemotherapy, radiotherapy of cancer. Lin J; Song T; Li C; Mao W Biochim Biophys Acta Mol Cell Res; 2020 May; 1867(5):118659. PubMed ID: 31978503 [TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3β inhibitors: A critical review. Xu M; Wang SL; Zhu L; Wu PY; Dai WB; Rakesh KP Eur J Med Chem; 2019 Feb; 164():448-470. PubMed ID: 30616053 [TBL] [Abstract][Full Text] [Related]
7. Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation. Ougolkov AV; Fernandez-Zapico ME; Bilim VN; Smyrk TC; Chari ST; Billadeau DD Clin Cancer Res; 2006 Sep; 12(17):5074-81. PubMed ID: 16951223 [TBL] [Abstract][Full Text] [Related]
8. Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions. Saraswati AP; Ali Hussaini SM; Krishna NH; Babu BN; Kamal A Eur J Med Chem; 2018 Jan; 144():843-858. PubMed ID: 29306837 [TBL] [Abstract][Full Text] [Related]
11. Glycogen synthase kinase 3β in tumorigenesis and oncotherapy (Review). He R; Du S; Lei T; Xie X; Wang Y Oncol Rep; 2020 Dec; 44(6):2373-2385. PubMed ID: 33125126 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of glycogen synthase kinase-3 beta induces apoptosis and mitotic catastrophe by disrupting centrosome regulation in cancer cells. Yoshino Y; Ishioka C Sci Rep; 2015 Aug; 5():13249. PubMed ID: 26292722 [TBL] [Abstract][Full Text] [Related]
13. Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Ougolkov AV; Fernandez-Zapico ME; Savoy DN; Urrutia RA; Billadeau DD Cancer Res; 2005 Mar; 65(6):2076-81. PubMed ID: 15781615 [TBL] [Abstract][Full Text] [Related]
14. Glycogen Synthase Kinase-3β as a Putative Therapeutic Target for Bipolar Disorder. Dandekar MP; Valvassori SS; Dal-Pont GC; Quevedo J Curr Drug Metab; 2018; 19(8):663-673. PubMed ID: 29283064 [TBL] [Abstract][Full Text] [Related]
15. Development of inhibitors targeting glycogen synthase kinase-3β for human diseases: Strategies to improve selectivity. Wei J; Wang J; Zhang J; Yang J; Wang G; Wang Y Eur J Med Chem; 2022 Jun; 236():114301. PubMed ID: 35390715 [TBL] [Abstract][Full Text] [Related]
16. Glycogen synthase kinase-3β inhibition depletes the population of prostate cancer stem/progenitor-like cells and attenuates metastatic growth. Kroon J; in 't Veld LS; Buijs JT; Cheung H; van der Horst G; van der Pluijm G Oncotarget; 2014 Oct; 5(19):8986-94. PubMed ID: 25344861 [TBL] [Abstract][Full Text] [Related]
17. Discovery of new GSK-3β inhibitors through structure-based virtual screening. Dou X; Jiang L; Wang Y; Jin H; Liu Z; Zhang L Bioorg Med Chem Lett; 2018 Jan; 28(2):160-166. PubMed ID: 29208522 [TBL] [Abstract][Full Text] [Related]
18. The role of glycogen synthase kinase-3β (GSK-3β) in endometrial carcinoma: A carcinogenesis, progression, prognosis, and target therapy marker. Chen S; Sun KX; Liu BL; Zong ZH; Zhao Y Oncotarget; 2016 May; 7(19):27538-51. PubMed ID: 27050373 [TBL] [Abstract][Full Text] [Related]
19. Glycogen synthase kinase-3β is a crucial mediator of signal-induced RelB degradation. Neumann M; Klar S; Wilisch-Neumann A; Hollenbach E; Kavuri S; Leverkus M; Kandolf R; Brunner-Weinzierl MC; Klingel K Oncogene; 2011 May; 30(21):2485-92. PubMed ID: 21217772 [TBL] [Abstract][Full Text] [Related]
20. The role of glycogen synthase kinase 3 beta in multiple sclerosis. Noori T; Dehpour AR; Sureda A; Fakhri S; Sobarzo-Sanchez E; Farzaei MH; Küpeli Akkol E; Khodarahmi Z; Hosseini SZ; Alavi SD; Shirooie S Biomed Pharmacother; 2020 Dec; 132():110874. PubMed ID: 33080467 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]